share_log

长城国瑞证券4月9日发布研报称，给予九洲药业（603456.SH）买入评级。评级理由主要包括：1）盈利能力有所提升，原料药业务承压；2）CDMO业务保持快速增长态势；3）多肽及偶联业务进展顺利。（每日经济新闻）

Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2)

Zhitong Finance ·  Apr 10 15:40
Great Wall Guorui Securities released a research report on April 9 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) Profitability has increased, putting pressure on the API business; 2) the CDMO business has maintained a rapid growth trend; and 3) the peptide and conjugation business is progressing smoothly. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment